The study included 257 patients with early therapeutic Alzheimer’s disease; 131 got Donneb, while 126 got placebo. The researchers found that Donenemab slowed cognitive and daily functional decline by 327% after 76 weeks in Alzheimer’s patients, compared with those who received a placebo. Not involved in this research, Maria Carrillo, …
Read More »Preliminary results indicate that experimental Alzheimer’s drug may slow cognitive decline in patients
